Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSABiotechnology
+$0.42 today
- Market cap
- $7.47B
- Beta
- 0.12
- P/E (TTM)
- 57.2
- EPS (TTM)
- $0.95
Volume 0.33M
Average 0.66M
KNSA Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Kiniksa Pharmaceuticals, Ltd.NASDAQ: KNSA
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q2 FY2026 depreciation & amortization of $472K rose 31.8% year over year, ahead of the +19.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.9% from the prior quarter. Over 3 fiscal years it compounded at -13.5% a year.
Context
- Depreciation & amortization amounted to 0.2% of revenue in FY2025, down 0.2 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +31.8% holds above the trailing-twelve-month pace of +19.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 1.55M USD
- Year-over-year change
- -8.3%
- 4-year CAGR
- -9.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.55M | -8.3% |
| FY2024 | 2024-12-31 | 1.7M | -27.6% |
| FY2023 | 2023-12-31 | 2.34M | -2.5% |
| FY2022 | 2022-12-31 | 2.4M | +2.0% |
| FY2021 | 2021-12-31 | 2.36M | — |
Depreciation & Amortization vs competitors
How KNSA compares with its peers on the latest reported figures
- KNSA's LTM Jun 2026 depreciation & amortization of $1.79M is the 4th highest of the 10 companies compared; the peer median is $379K.
- Its year-over-year change of +19.2% is the 2nd highest of 9, against a peer median of -9.9%.
- Depreciation & amortization amounts to 0.2% of revenue for KNSA, versus a peer median of 4.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $14.4M | -22.3% | +20.4% | 2.1% | |
| LTM Mar 2026 | $11.75M | -9.8% | -6.6% | 3.2% | |
| LTM Mar 2026 | $2.43M | +1.2% | +1.2% | 1.0% | |
| LTM Jun 2026 | $1.79M | +19.2% | -13.5% | 0.2% | |
| LTM Mar 2026 | $528K | +7.3% | -17.1% | 6.3% | |
| LTM Jun 2026 | $379K | -11.0% | +42.8% | 19.9% | |
| LTM Sep 2026 | $378K | -10.0% | +28.4% | 5.3% | |
| LTM Mar 2026 | $226K | -16.3% | +27.5% | 383.1% | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $163K | +129.6% | -10.0% | — |
| LTM Sep 2026 | $0 | — | +72.0% | 0.0% | |
| Peer median (excluding KNSA) | $379K | -9.9% | +20.4% | 4.3% | |
Competitors are the stored peer set for KNSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 38.54M | 220.18M | 270.26M | 423.24M | 677.56M |
| Cost of Revenue | 9.1M | 22.9M | 56.52M | 60.91M | 307.41M |
| Gross Profit | 29.44M | 197.29M | 213.74M | 362.33M | 370.15M |
| Gross Margin | 76.4% | 89.6% | 79.1% | 85.6% | 54.6% |
| Research & Development | 99.3M | 65.49M | 76.1M | 111.62M | 96.85M |
| Selling, General & Admin | 85.95M | 97.95M | 129.43M | 168.01M | 196.27M |
| Operating Expenses | 186.08M | 187.51M | 238.93M | 407.95M | 292.93M |
| Depreciation & Amortization | 2.36M | 2.4M | 2.34M | 1.7M | 1.55M |
| EBITDA | (154.18M) | 13.43M | (14.31M) | (34.46M) | 90.42M |
| EBITDA Margin | -400.0% | 6.1% | -5.3% | -8.1% | 13.3% |
| Operating Income | (156.64M) | 9.77M | (25.2M) | (45.62M) | 77.22M |
| Operating Margin | -406.4% | 4.4% | -9.3% | -10.8% | 11.4% |
| Interest Income | 97K | 1.25M | 8.54M | 9.46M | 11.65M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 97K | 1.25M | 8.54M | 9.46M | 11.65M |
| Income Before Tax | (156.54M) | 11.03M | (16.65M) | (36.15M) | 88.87M |
| Pre-Tax Margin | -406.1% | 5.0% | -6.2% | -8.5% | 13.1% |
| Income Tax Expense | 1.39M | (172.34M) | (30.74M) | 7.04M | 29.86M |
| Net Income | (157.92M) | 183.36M | 14.08M | (43.19M) | 59.01M |
| Net Margin | -409.7% | 83.3% | 5.2% | -10.2% | 8.7% |
| EPS (Basic) | (2.30) | 2.64 | 0.20 | (0.60) | 0.80 |
| EPS (Diluted) | (2.30) | 2.60 | 0.20 | (0.60) | 0.75 |
| Weighted Avg Shares | 68.58M | 69.38M | 70.06M | 71.42M | 74.2M |
| Weighted Avg Shares (Diluted) | 68.58M | 70.42M | 71.92M | 71.42M | 78.98M |
Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSA
Intrinsic Alpha fair value
Locked
Current Price
$95.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.